-
1921 PLIVA is founded
In Karlovac, companies "Isis" (Zagreb) and "Chinion" (Budapest) found the company "Kaštel" d.d., PLIVA's predecessor
-
1935 Future Nobel Prize winner joins PLIVA
Vladimir Prelog, PhD, later Nobel Prize winner (1975), joins the company and begins research in Kaštel
-
1936 Sulfonamides
Kaštel becomes one of the first sulfonamide producers in the world
-
1941 PLIBAH becomes PLIVA
PLIBAH renamed PLIVA - the State Institute for Production of Medicines and Vaccines
-
1945 "Kaštel" d.d.
"Kaštel" becomes part of PLIVA
-
1952 Research Institute
Osnovan Istraživački Institut PLIVE.
-
1959 Oxytetracycline and vitamin B6 production started
-
1965 The first FDA approval
PLIVA's oxytetracycline production plant received the approval by the US Food and Drug Administration (FDA), the first of more than 30 DMF submissions approved by the FDA
-
1971 Metacycline is patented
-
1980 PLIVA's own antibiotic
PLIVA's original macrolide antibiotic azithromycin is patented
-
1986 Agreement with a US-based company
PLIVA signs azithromycin licensing agreement with Pfizer for the USA, Western Europe and Japan
-
1988 SUMAMED
Azithromycin launched under PLIVA's brand name Sumamed
-
1991 Zithromax
Azithromycin launched under Pfizer's brand name Zithromax on US and Western Europe markets
-
1996 PLIVA's shares listed on Zagreb and London Stock Exchanges
Initial listing of PLIVA’s shares on the Zagreb and London Stock Exchanges
-
1997 – 2003 International acquisitions
International expansion: Poland (Polfa Krakow, 1997); the Czech Republic (Lachema, 1999); Great Britain (Dominion, 2000); Germany (AWD, 2001);
-
2005 Agreements
PLIVA signs biological partnership agreements with Mayne Pharmaceuticals and Barr Laboratories; generic azithromycin launched in USA
-
2006 Global leader
AWD manufacturing plant in Germany divested. Exit from the proprietary business. PLIVA becomes part of the European generic arm of Barr Pharmaceuticals, Inc., thus creating one of the leading global generic pharmaceuticals companies.
-
2008 Teva Group
PLIVA becomes member of the Teva Group, the largest generic pharmaceutical company
-
2011 New Investment Cycle
PLIVA acquired the company Unimed d.o.o. in Serbia. PLIVA has entered a new investment cycle in Croatia. It plans to invest USD 120 million over the next three to five years, in the new production plant in Savski Marof and the expansion of production capacities in Zagreb.
